Categories
Thirteen abstracts by our Qurit lab and our collaborators were accepted and published by the European Association of Nuclear Medicine (EANM) 2022 Congress, spanning areas of dosimetry, theranostics, PBPK modeling, radiomics, AI and optimized image generation.
- C. Uribe, N. Colpo, J. Brosch-Lenz, C. Dellar, W. Parulekar, F. Saad, K. Chi, K. Zukotynski, J. Beauregard, F. Benard
Calibration procedures for multi-centre dosimetry studies with 177Lu radiopharmaceuticals: early experience from the Canadian cancer trial group PR.21 trial (NCT 04663997)
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S186, 2022. - M. R. Salmanpour, M. Hosseinzadeh, M. Ramezani, S. M. Rexaeijo, A. Rahmim
Reliable and reproducible tensor radiomics features in prediction of survival in head and neck cancer
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S20, 2022. - M. R. Salmanpour, M. Ramezani, S. Marandi, M. Hosseinzadeh, S. M. Rezaeijo, A. Rahmim
Deep versus handcrafted tensor radiomics features: application to survival prediction in head and neck cancer
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S245, 2022. - A. Fathi Jouzdani, A. Gorji, M. Hosseinzadeh, A. Rahmim, M. R. Salmanpour
Prediction of cognitive decline in Parkinson's disease using deep and handcrafted radiomics features
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S195, 2022. - H. Konair, C. Miller, A. Rahmim, P. Schaffer, C. Uribe
Cellular dosimetry from the 225AC decay chain: impact of progeny internalization and migration
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S207, 2022. - N. Shakouifar, M. Soltani, F. Moradi Kashkooli, B. Saboury, A. Rahmim
Effect of tumor receptor density on time integrated activity of radiopharmaceutical therapy in tumors via physiologically based pharacokinetic modeling
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S209, 2022. - J. Brosch-Lenz, X. Hou, I. Bloise, N. Colpo, W. R. Parulekar, C. Dellar, F. Saad, K. Chi, D. Wilson, F. Benard, A. Rahmim, C. Uribe
Assessing the impact of dosimetry method on healthy organ and lesion absorbed dose estimates for 177Lu-PSMA-617 therapy of prostate cancer: early experience from the Canadian cancer trials group of PR21 trial (NCT 04663997)
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S394, 2022. - J. Brosch-Lenz, A. Rahmim, J. Sunderland, E. Frey, Y.K. Dewaraja, C. Uribe
Impact of dosimetry method on organ and tumor absorbed dose estimates for lutetium-177-DOTATATE therapy of neuroendoctrine tumors
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S393, 2022. - A. Fele-Paranj, C. Uribe, B. Saboury, A. Rahmim
Open-source, modular, high-computational-throughput physiologically based pharmacokinetics (PBPK) modeling fine-tuned for optimization of radiopharmaceutical therapy
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S398, 2022. - A. Golzaryan, M. Soltani, F. M. Kashkooli, B. Saboury, A. Rahmim
Impact of metronomic radiopharmaceutical therapy on tumor and organ-at-risk absorbed doses: a PBPK modeling approach
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S392, 2022. - R. Fedrigo, G. Chausse, R. Coope, F. Benard, A. Rahmim, C. Uribe
Characterization of salivary gland uptake and volume in PSMA PET imaging: novel phantom study approach
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S603, 2022. - R. Fedrigo, D. J. Kadrmas, R. Coope, F. Benard, A. Rahmim, C. Uribe
Impact of regularized reconstruction on image quality of metastases in PSMA PET images
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S608, 2022. - T. Zare, P. Sheikhzadeh, A. Rahmim, B. Teimourian Fard, P. Ghafarian, M. R. Ay
Optimization of time coincidence window and energy window for dedicated brain PET: a simulation study
Eur. J. Nucl. Med. Mol. Imaging, vol. 49 (suppl. 1): S959, 2022
Share This
